Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.44 |
| ▸ | IGF1R | P08069 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.39 |
| ▸ | CYP4F11 | Q9HBI6 | 1/20 | 0.39 |
| ▸ | CYP4F12 | Q9HCS2 | 1/20 | 0.39 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6301819 | 0.86 | ALDH1A1 (0.52) | ALDH1A1SKP2CYP4A11CYP4F2CA2 | |
| SCHEMBL31556195 | 0.84 | SKP2 (0.50) | ALDH1A1SKP2IGF1RALOX15CNR1 | |
| SCHEMBL27848429 | 0.83 | IGF1R (0.52) | ALDH1A1IGF1RALOX15CA2BCHE | |
| SCHEMBL3192065 | 0.83 | SKP2 (0.47) | ALDH1A1SKP2CYP4A11CYP4F2IGF1R | |
| SCHEMBL2913327 | 0.83 | ESR1 (0.61) | ALDH1A1SKP2IGF1RALOX15CA2 | |
| SCHEMBL23093076 | 0.82 | SKP2 (0.70) | ALDH1A1SKP2CYP4A11CYP4F2IGF1R | |
| SCHEMBL586296 | 0.82 | DAO (0.46) | ALDH1A1SKP2CYP4A11CYP4F2IGF1R | |
| SCHEMBL17471720 | 0.82 | CYP4A11 (0.41) | ALDH1A1SKP2CYP4A11CYP4F2IGF1R | |
| SCHEMBL81865 | 0.82 | SLC6A2 (0.46) | SKP2CYP4A11CYP4F2IGF1RALOX15 | |
| SCHEMBL81132 | 0.82 | IGF1R (0.44) | ALDH1A1SKP2CYP4A11CYP4F2IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170217997-A1 | PHOTO-CLEAVABLE PRIMER COMPOSITIONS AND METHODS OF USE | ORMCO CORPORATION | 2017-08-03 | — | — | US | disclosed |
| EP-2168944-B1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-05-11 | — | — | EP | disclosed |
| EP-2168944-B1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-05-11 | — | — | EP | disclosed |
| WO-2014151953-A1 | COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2014-09-25 | — | — | WO | disclosed |
| US-8188082-B2 | 5,6,7,8-tetrahydro-imidazo[1,5-α]pyrazine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-05-29 | — | — | US | disclosed |
| US-8129361-B2 | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8129361-B2 | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8129361-B2 | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| EP-2125823-B1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-02-15 | — | — | EP | disclosed |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-07-15 | — | — | US | disclosed |
| EP-0788357-A1 | A METHOD OF TREATING URINARY BLADDER DYSFUNCTIONS | NOVO NORDISK A/S (DK) | 1997-08-13 | — | — | EP | disclosed |
| US-5565475-A | Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives | MUHLHAUSER MARK A (US) | 1996-10-15 | — | — | US | disclosed |
| EP-0734259-A1 | ANTIPSYCHOTIC METHOD | NOVO NORDISK A/S (DK) | 1996-10-02 | — | — | EP | disclosed |
| EP-0732925-A1 | A METHOD OF TREATING GASTROINTESTINAL MOTILITY DISORDERS | NOVO NORDISK A/S (DK) | 1996-09-25 | — | — | EP | disclosed |
| US-5545638-A | USING A 3-(TETRAHYDROPYRID-3-YL-) SUBSTITUTED (OXA- OR THIA-)DIAZOLE COMPOUND | NOVO NORDISK A/S (DK) | 1996-08-13 | — | — | US | disclosed |
| WO-1996014066-A1 | A METHOD OF TREATING URINARY BLADDER DYSFUNCTIONS | NOVO NORDISK A/S (DK) | 1996-05-17 | — | — | WO | disclosed |
| EP-0687265-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1995-12-20 | — | — | EP | disclosed |
| WO-1995017185-A1 | A METHOD OF TREATING GASTROINTESTINAL MOTILITY DISORDERS | NOVO NORDISK A/S (DK) | 1995-06-29 | — | — | WO | disclosed |
| WO-1995005174-A1 | ANTIPSYCHOTIC METHOD | NOVO NORDISK A/S (DK) | 1995-02-23 | — | — | WO | disclosed |
| WO-1994020495-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1994-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217997-A1 | PHOTO-CLEAVABLE PRIMER COMPOSITIONS AND METHODS OF USE | SP1, GPER1, ESR1 | ALDH1A1 869/4885SKP2 7/4885CYP4A11 1368/4885 |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | HLA-B, HLA-A, HLA-C | ALDH1A1 646/4885SKP2 3298/4885CYP4A11 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.